Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cambridge Heart, Inc. (NasdaqNM:CAMH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
July 25Conference call: Cambridge Heart Earnings (Q2 2001)
Location
1 Oak Park Drive
Bedford, MA 01730
Phone: (781) 271-1200
Fax: (781) 275-8431
Email: bobp@cambridgeheart.com
Employees (last reported count): 35
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 41%
·Over the last 6 months:
 · 2 insider buys; 6,000  shares
 · one insider sell; 30.0K shares
  (0.4% of insider shares)
·Institutional: 30% (51% of float)
(21 institutions)
·Net Inst. Selling: 142.0K shares (+2.84%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cambridge Heart, Inc. is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest and the early detection of coronary artery disease. Its proprietary technology, Microvolt T-Wave Alternans is the only diagnostic tool cleared by the U.S. Food and Drug Administration to non-invasively measure Microvolt levels of T-Wave Alternans, an extremely subtle beat-to-beat fluctuation in a patient's heartbeat. The Company's CH 2000 Alternans System (CH 2000), Heartwave System and Heartwave EP System, and Micro-V Alternans Sensors have all received 510(k) clearance from the FDA for sale in the United States. Its CH 2000 and Micro-V Alternans Sensors have received the CE mark for sale in Europe and have been approved for sale by the Ministry of Health in Japan.
More from Market Guide: Expanded Business Description

Financial Summary
Cambridge Heart, Inc. is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. For the three months ended 3/31/01, revenues increased 64% to $678 thousand. Net loss decreased 18% to $1.7 million. Revenues reflect increased sales of Microvolt T-Wave Alternan products. Net loss was partially offset by increased S/G/A expenses due to the expansion of the U.S. sales organization.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 739; after tax earnings were -1,702. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Jeffrey Arnold, 51
Chairman
$312K
David Chazanovitz, 50
Pres, CEO, Chief Operating Officer
--  
Robert Palardy, 52
CFO, VP of Fin. and Admin.
154K
James Sheppard, 41
VP of Operations
142K
Eric Dufford, 42
VP of Sales and Marketing and Sec.
182K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CAMHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$1.781
Recent Price$2.08 
52-Week High
on 29-Sep-2000
$5.00 
Beta1.40 
Daily Volume (3-month avg)16.4K
Daily Volume (10-day avg)28.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-44.5%
52-Week Change
relative to S&P500
-25.6%
Share-Related Items
Market Capitalization$35.5M
Shares Outstanding17.1M
Float10.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.64 
Earnings (ttm)-$0.43 
Earnings (mrq)-$0.10 
Sales (ttm)$0.15 
Cash (mrq*)$0.56 
Valuation Ratios
Price/Book (mrq*)3.23 
Price/EarningsN/A 
Price/Sales (ttm)14.02 
Income Statements
Sales (ttm)$2.46M
EBITDA (ttm*)-$7.18M
Income available to common (ttm)-$7.04M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-54.42%
Return on Equity (ttm)-60.45%
Financial Strength
Current Ratio (mrq*)7.81 
Debt/Equity (mrq*)0 
Total Cash (mrq)$7.80M
Short Interest
As of 8-Aug-2001
Shares Short80.0K
Percent of Float0.8%
Shares Short
(Prior Month)
88.0K
Short Ratio8.00 
Daily Volume10.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.